Navigation Links
Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
Date:1/12/2009

RIDGEFIELD, Conn., Jan. 12 /PRNewswire/ -- Boehringer Ingelheim today announced the appointment of Albert Ros as executive vice president of Sales and Marketing for the company's Prescription Medicines Business. In his new role, Ros will lead the U.S. sales and marketing strategy of Boehringer Ingelheim's core brands.

"We are pleased to have Albert in such an important leadership role," said J. Martin Carroll, President and Chief Executive Officer, Boehringer Ingelheim Corporation. "Albert is a valuable member of the Boehringer Ingelheim team and he possesses an impressive range of global sales and marketing experience."

Ros has been with Boehringer Ingelheim for 14 years and previously served as Head of Boehringer Ingelheim's Corporate Division for Marketing of Prescription Medicines. In this position, which he held since 2005, Ros led the development of four global products including Spiriva(R), Flomax(R), Mirapex(R) and Micardis(R). Previously, Ros served as the country manager for Boehringer Ingelheim Brazil and the business unit head of Boehringer Ingelheim Spain.

Ros earned a pharmacy degree from the University of Barcelona, a master's degree in business administration from ESADE Business School in Barcelona, and a post graduate degree in general management from IESE Business School in Barcelona. Ros and his wife and three sons will relocate to Ridgefield, Connecticut in early 2009.

About Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. For more information, please visit http://us.boehringer-ingelheim.com.


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® ... for forty years and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to ... Show on May 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst ...
(Date:5/24/2016)... Forest Lake, Minnesota (PRWEB) , ... May 24, ... ... his 13th mission trip to the Dominican Republic on September 21, 2016. Dr. ... Biology from Northwestern, serves with ChiroMission, a not-for-profit organization promoting health and wellness ...
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion ... and safety labels , has been featured in the National Electrical Manufacturers ... eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The publication ...
(Date:5/24/2016)... ... 2016 , ... Researchers from Catholic Health Initiatives (CHI) presented ... complications from percutaneous coronary intervention (PCI). The data, presented at the annual meeting ... a 40% reduction in risk-adjusted bleeding event rates over a two-year period across ...
(Date:5/24/2016)... ... May 24, 2016 , ... Applications such as ... are widely used for cell and protein analysis. Keeping updated on practical considerations ... efficiency in these areas. , LabRoots introduces a new complementary interactive virtual ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... May 20, 2016 The Biotech ... believe that the industry is not far from recovering. ... ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. ... ATHX ), Aralez Pharmaceuticals Inc. (NASDAQ: ... INFI ). Sign up for your free trading alerts ...
(Date:5/19/2016)... 19,2016 Cellvizio Highlighted in ... Week Meeting and 91 st Congress of ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... announced that its Cellvizio platform is being highlighted ... during the month of May. The first meeting ...
(Date:5/19/2016)... , May 19, 2016 , The ... bstract # 8006)   The conclusions ... of the treated patients with 90% of the m ... months or more . Seventy two percent of the patients had ... announces the positive results from a Phase I study of plitidepsin in combination ...
Breaking Medicine Technology: